125 related articles for article (PubMed ID: 32064041)
1. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.
Montaudié H; Viotti J; Combemale P; Dutriaux C; Dupin N; Robert C; Mortier L; Kaphan R; Duval-Modeste AB; Dalle S; De Quatrebarbes J; Stefan A; Brunet-Possenti F; Kogay M; Picard-Gauci A; Poissonnet G; Peyrade F
Oncotarget; 2020 Jan; 11(4):378-385. PubMed ID: 32064041
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
Dereure O; Missan H; Girard C; Costes V; Guillot B
Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma.
Marin-Acevedo JA; Withycombe BM; Kim Y; Brohl AS; Eroglu Z; Markowitz J; Tarhini AA; Tsai KY; Khushalani NI
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370790
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature.
Jarkowski A; Hare R; Loud P; Skitzki JJ; Kane JM; May KS; Zeitouni NC; Nestico J; Vona KL; Groman A; Khushalani NI
Am J Clin Oncol; 2016 Dec; 39(6):545-548. PubMed ID: 24879468
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
10. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
11. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
14. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
[TBL] [Abstract][Full Text] [Related]
17. Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis.
Palmer JD; Schneider CJ; Hockstein N; Hanlon AL; Silberg J; Strasser J; Mauer EA; Dzeda M; Witt R; Raben A
Oral Oncol; 2018 Mar; 78():102-107. PubMed ID: 29496036
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of cetuximab combined with radical radiotherapy in the treatment of locally advanced sinonasal squamous cell carcinoma.
Qiu X; Yang J
J BUON; 2018; 23(4):1111-1117. PubMed ID: 30358219
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]